Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/30/2002EP1251859A1 Novel compounds
10/30/2002EP1251858A2 Podophyllotoxin compositions
10/30/2002EP1251856A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
10/30/2002EP1251855A1 Selective estrogen receptor modulators in combination with estrogens
10/30/2002EP1251854A2 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
10/30/2002EP1251853A1 Transdermal therapeutic system for the administration of zaleplon
10/30/2002EP1251851A1 Treating allergic and inflammatory conditions
10/30/2002EP1251848A1 Gyrase inhibitors and uses thereof
10/30/2002EP1251843A1 Compositions for delivery of a cortisol antagonist
10/30/2002EP1251840A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
10/30/2002EP1251839A2 Use of cox-2 inhibitors for the treatment of constipation
10/30/2002EP1251837A2 Compounds and methods for modulating cerebral amyloid angiopathy
10/30/2002EP1251831A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
10/30/2002EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002EP1251824A2 Methods of using a beverage composition for treating dental erosion
10/30/2002EP1152731A4 A skin care composition that mediates cell to cell communication
10/30/2002EP1017412A4 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
10/30/2002EP1005449B1 3-aryl-succinamido-hydroxamic acids, methods for producing said acids and medicaments containing the same
10/30/2002EP0991410B1 Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
10/30/2002EP0854863B1 Esters and amides as pla2 inhibitors
10/30/2002EP0852225B1 Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
10/30/2002EP0831835B1 Treating anorexia
10/30/2002EP0799221B1 Quinazolines as inhibitors of endothelin converting enzyme
10/30/2002EP0793660B1 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
10/30/2002EP0726911B1 Treatment of hematologic disorders with a igf-1/igfbp-3 complex
10/30/2002EP0695187B1 Inhibition, control and regression of angiogenesis with hyaluronic acid or hyaluronic acid and nsaid
10/30/2002EP0689449B1 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
10/30/2002CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002CN1377414A Self-cleaving RNA sequences and their use for the control of protein synthesis
10/30/2002CN1377408A The PRV-1 gene and use thereof
10/30/2002CN1377368A 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
10/30/2002CN1377366A 5-hydroxysapogenin derivatives with anti-dementia activity
10/30/2002CN1377365A Eplerenone crystalline form exhibiting enhanced dissolution rate
10/30/2002CN1377357A Pyrazolo [4,3-d] pyrimidines
10/30/2002CN1377356A Certain alkylene diamine-substituted heterocycles
10/30/2002CN1377355A Amino substituted pyrazolo [1,5-2]-1,5-pyrimidines and pyrazolo [1,5-2]-1,3, 5-triazines
10/30/2002CN1377354A Certain alkylene diamine-substituted pyrazolo [1,5-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
10/30/2002CN1377352A Selective antagonists of A28 adenosine receptors
10/30/2002CN1377349A Quiunclidine compounds and drugs containing the same as the active ingredient
10/30/2002CN1377348A 4,5-diaryloxazole compounds with prostaglandin 12 (PG12) agonistic activity
10/30/2002CN1377347A 药学活性磺酰胺衍生物 Pharmaceutically active sulfonamide derivatives
10/30/2002CN1377346A Z-pyrazoline-5-ones
10/30/2002CN1377344A Inhibitor of cysteinyl aspartic acid proteinase
10/30/2002CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002CN1377276A Protein polymerization inhibitors and methods of use
10/30/2002CN1377273A Antiobestic agents
10/30/2002CN1377271A Use of thienopyrimidines
10/30/2002CN1377268A Cell adhesion inhibitors
10/30/2002CN1377267A Retard form containing 2-lipoic acid (derivatives)
10/30/2002CN1377259A ACE-2 inhibiting compounds and methods of use thereof
10/30/2002CN1377235A Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions
10/30/2002CN1376664A Propynyl or diene diaryl compounds
10/30/2002CN1376470A Ointment for dispelling wind and relieving rigidity of muscles and joints and its preparing process
10/30/2002CN1093536C 5-lipoxygenase inhibitor
10/30/2002CN1093407C Medicine for nourishing yin and strengthening body resistance and producing method thereof
10/30/2002CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002US6472562 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
10/29/2002US6472534 Treating tetrahydrofuran derivativ with an oxophilic electrophilic reagent in a manner that is effective to provide the oxazoline compound
10/29/2002US6472531 Single reaction vessel acylation and deetherification production of crystalline, high purity chemical intermediates for such as pharmaceuticals
10/29/2002US6472529 Viricides
10/29/2002US6472526 Shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in pharmaceutical composition and intermediates
10/29/2002US6472521 Oligonucleotides for the inhibition of human eg5 expression
10/29/2002US6472511 Stimulation of an immune response with antibodies labeled with the α-galactosyl epitope
10/29/2002US6472505 Treatment of physiological conditions capable of being modulated by agonist or antagonist activity on parathyroid hormone receptors
10/29/2002US6472434 Vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives,
10/29/2002US6472423 Pharmaceutical composition
10/29/2002US6472418 Non-peptide NK1 receptors antagonists
10/29/2002US6472413 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them
10/29/2002US6472412 Compounds as PDE IV and TNF inhibitors
10/29/2002US6472411 Advanced glycation end-product intermediaries and post-amadori inhibition
10/29/2002US6472406 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
10/29/2002US6472404 HIV protease inhibitors
10/29/2002US6472400 Advanced gylcation end-product intermediaries and post-Amadori inhibition
10/29/2002US6472399 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
10/29/2002US6472398 Spiropiperidine derivatives as melanocortin receptor agonists
10/29/2002US6472396 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/29/2002US6472392 Triazole compounds and the use thereof as dopamine-D3 -ligands
10/29/2002US6472388 Psychotherapeutic agents.
10/29/2002US6472386 Cyclic diamine compound with 5-membered ring groups
10/29/2002US6472368 Compounds and methods for modulating adhesion molecule function
10/29/2002US6472367 Compounds and methods for modulating OB-cadherin mediated cell adhesion
10/29/2002US6472197 GRB2 associating polypeptides and nucleic acids encoding therefor
10/29/2002US6472180 A polynucleotide which encodes a truncated fragment of the hcv ns3 (hepatitis c virus)ns3 protein helicase fragment, such truncated fragment retaining helicase activity and having about 50 amino acids of carboxy terminus deleted
10/29/2002US6472178 Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
10/29/2002US6472145 A mobile ionophore composition effective to modulate app catabolism without substantially altering the viability of app-containing cells; inhibits amyloid deposition; alzheimer's disease; nontoxic
10/29/2002US6471997 Antagonist of calcitonin gene related peptide, cgrp and/or of substance p; cosmetic
10/29/2002US6471959 Human transferase
10/29/2002EP1144613A4 Methods for making proteins containing free cysteine residues
10/29/2002CA2173102C Dna sequence coding for a bmp receptor
10/29/2002CA2063431C Receptors for fibroblast growth factors
10/28/2002WO2001082909A2 2-acyl indol derivatives and their use as anti-tumour agents
10/28/2002CA2407677A1 2-acyl indol derivatives and their use as anti-tumour agents
10/25/2002WO2001083451A1 Novel bicyclic compounds
10/25/2002EP1194142A4 Salts of cis -4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexan-1-carboxylate!
10/25/2002EP1017376A4 Method of treating heart failure
10/25/2002CA2383175A1 Methods and kits for treating depression or preventing deterioration of cognitive function
10/24/2002WO2002084294A2 Gastrointestinal glutathione peroxidase in hepatitis c virus infections
10/24/2002WO2002084249A2 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218
10/24/2002WO2002083892A2 Mutants of desoxycytidine kinase having extended enzymatic activity
1 ... 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 ... 1564